Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2026-05-13 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
Transaction in Own Shares Classification · 85% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding its on-market share repurchase plan, describing repurchases under its general mandate and listing rule compliance. This is a report of the company buying back its own shares, which fits the “Transaction in Own Shares” category.
2026-05-13 English
VOLUNTARY ANNOUNCEMENT - CSTONE INITIATES NATIONWIDE COMMERCIAL SUPPLY OF LOCALLY MANUFACTURED PRALSETINIB CAPSULES
Regulatory Filings Classification · 92% confidence The document is a voluntary business update by CStone Pharmaceuticals announcing the initiation of commercial supply of its locally manufactured drug. It contains no detailed financial results, no vote outcomes, no management changes, and no regulatory compliance filings beyond the voluntary business announcement. It does not constitute an earnings release, interim report, prospectus, or capital markets transaction. This falls into the fallback category for miscellaneous regulatory announcements.
2026-05-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings Classification · 100% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for CStone Pharmaceuticals for the month ended 30 April 2026. It includes detailed data on authorized share capital, issued shares, treasury shares, share options, and confirmations related to compliance with listing rules. The document is a regulatory submission reporting changes in share capital and share movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a substantive regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-05-07 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Environmental & Social Information Classification · 95% confidence The document is titled “2025 Environmental, Social and Governance Report” and contains detailed chapters on the company’s environmental performance (e.g., greenhouse gas emissions), social initiatives (e.g., community engagement, employment management), and governance structures (e.g., ESG governance, board statements). It is the full ESG report rather than an announcement, regulatory notice, or financial statement. This matches the Environmental & Social Information category.
2026-04-27 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled "2025 Annual Report" and contains detailed sections typical of an annual report, including corporate information, financial highlights, business highlights, management discussion and analysis, directors and senior management, corporate governance report, independent auditor's report, and comprehensive financial data for the year ended December 31, 2025. The length of the document is substantial (15,000 characters), and it includes actual financial statements and analysis, not just an announcement or summary. The presence of an independent auditor's report within the document further supports that this is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-27 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 97% confidence The document is a statutory “Next Day Disclosure Return” (HKEx Form FF305) reporting changes in issued shares under Listing Rule 13.25A/17.27A (issue of new shares under an RSU scheme). It details the class and number of shares issued, opening/closing balances, and confirmations of compliance. This is not a general annual or financial report but a specific corporate action announcement concerning share capital changes. It therefore falls under Share Issue/Capital Change (SHA).
2026-04-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.